Search
Main Menu
Main Content
Fermer
Choose language
FR
EN
Accessibility
Change contrast :
Standards
Reinforced
icone
HAS profile
Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest
International relations and projects
Publications
English content
Medicines
Opinions on medical devices
INAHTA briefs
French website
Chercher
Recherche
icone plus
English content
Les recommandations et guides
Les médicaments
Les actes professionnels
Les dispositifs médicaux
Les médecins accrédités
Les articles d'information
Les établissements de santé
Chercher
My account
My account
Email alert Subscription
Newsletter Subscription
My search
Refresh
Please fill in your email address to retrieve your email alerts subscriptions.
New subscription
Please fill in your email address to retrieve your newsletter subscriptions.
You do not have a saved search
Mon Compte
Sélection
No element in selection
Favoris
Sélection
Établissements de santé
Contact
Abonnez-vous aux actualités
2 results
Active substance : nilotinib
OK
Chercher
Filter
Topic
Diagnostic and therapeutic techniques
(2)
Plus ...
Drug therapy
(1)
Diagnostic techniques and procedures
(1)
Plus ...
Biology (laboratory tests)
(1)
Diseases and conditions
(2)
Plus ...
Blood and lymphatic diseases
(2)
Plus ...
Hematologic cancers
(2)
Population groups
(1)
Plus ...
Paediatrics
(1)
Content type
Drugs, devices and medical acts
(2)
Plus ...
Medicine
(1)
Health technology assessment
(1)
Language
Français
(2)
Active substance
cytarabine
(1)
nilotinib
(2)
tyrosine
(1)
More filter
Save your search
Search Export
Drugs, devices and medical acts
- 2 results
TASIGNA (nilotinib)
Medicine
- Posted on 12/12/2018 - Mis à jour le 12/6/2019
Add to
my selection
Assessment of BCR-ABL fusion gene testing or quantification using RT-PCR in the diagnosis and therapeutic follow-up of chronic myeloid leukaemias and acute lymphoblastic leukaemias - INAHTA Brief
Health technology assessment
- Posted on 13/11/2017
Download
document
Add to
my selection
Français
English
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
1drXBD3RffPEWLBd